Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 131

1.

ABCB1 gene polymorphisms are associated with adverse reactions in fluoropyrimidine-treated colorectal cancer patients.

Gonzalez-Haba E, García MI, Cortejoso L, López-Lillo C, Barrueco N, García-Alfonso P, Alvarez S, Jiménez JL, Martín ML, Muñóz-Fernández MA, Sanjurjo M, López-Fernández LA.

Pharmacogenomics. 2010 Dec;11(12):1715-23. doi: 10.2217/pgs.10.159.

PMID:
21142915
2.

Germline TYMS genotype is highly predictive in patients with metastatic gastrointestinal malignancies receiving capecitabine-based chemotherapy.

Joerger M, Huitema AD, Boot H, Cats A, Doodeman VD, Smits PH, Vainchtein L, Rosing H, Meijerman I, Zueger M, Meulendijks D, Cerny TD, Beijnen JH, Schellens JH.

Cancer Chemother Pharmacol. 2015 Apr;75(4):763-72. doi: 10.1007/s00280-015-2698-7. Epub 2015 Feb 13.

PMID:
25677447
3.

MTHFR polymorphisms and capecitabine-induced toxicity in patients with metastatic colorectal cancer.

van Huis-Tanja LH, Gelderblom H, Punt CJ, Guchelaar HJ.

Pharmacogenet Genomics. 2013 Apr;23(4):208-18. doi: 10.1097/FPC.0b013e32835ee8e1.

PMID:
23407049
4.

Relationship between single nucleotide polymorphisms and haplotypes in DPYD and toxicity and efficacy of capecitabine in advanced colorectal cancer.

Deenen MJ, Tol J, Burylo AM, Doodeman VD, de Boer A, Vincent A, Guchelaar HJ, Smits PH, Beijnen JH, Punt CJ, Schellens JH, Cats A.

Clin Cancer Res. 2011 May 15;17(10):3455-68. doi: 10.1158/1078-0432.CCR-10-2209. Epub 2011 Apr 15.

5.

A polymorphism in the cytidine deaminase promoter predicts severe capecitabine-induced hand-foot syndrome.

Caronia D, Martin M, Sastre J, de la Torre J, García-Sáenz JA, Alonso MR, Moreno LT, Pita G, Díaz-Rubio E, Benítez J, González-Neira A.

Clin Cancer Res. 2011 Apr 1;17(7):2006-13. doi: 10.1158/1078-0432.CCR-10-1741. Epub 2011 Feb 16.

6.

Capecitabine (Xeloda) improves medical resource use compared with 5-fluorouracil plus leucovorin in a phase III trial conducted in patients with advanced colorectal carcinoma.

Twelves C, Boyer M, Findlay M, Cassidy J, Weitzel C, Barker C, Osterwalder B, Jamieson C, Hieke K; Xeloda Colorectal Cancer Study Group..

Eur J Cancer. 2001 Mar;37(5):597-604.

PMID:
11290435
7.

Capecitabine: a review.

Walko CM, Lindley C.

Clin Ther. 2005 Jan;27(1):23-44. Review.

PMID:
15763604
8.

The effect of COX-2 inhibitor on capecitabine-induced hand-foot syndrome in patients with stage II/III colorectal cancer: a phase II randomized prospective study.

Zhang RX, Wu XJ, Lu SX, Pan ZZ, Wan DS, Chen G.

J Cancer Res Clin Oncol. 2011 Jun;137(6):953-7. doi: 10.1007/s00432-010-0958-9. Epub 2010 Nov 27.

PMID:
21113620
9.

Potential of dihydropyrimidine dehydrogenase genotypes in personalizing 5-fluorouracil therapy among colorectal cancer patients.

Teh LK, Hamzah S, Hashim H, Bannur Z, Zakaria ZA, Hasbullani Z, Shia JK, Fijeraid H, Md Nor A, Zailani M, Ramasamy P, Ngow H, Sood S, Salleh MZ.

Ther Drug Monit. 2013 Oct;35(5):624-30. doi: 10.1097/FTD.0b013e318290acd2.

PMID:
23942539
10.

ABCB1 gene polymorphisms and haplotype analysis in colorectal cancer.

Panczyk M, Balcerczak E, Piaskowski S, Jamroziak K, Pasz-Walczak G, Mirowski M.

Int J Colorectal Dis. 2009 Aug;24(8):895-905. doi: 10.1007/s00384-009-0724-0. Epub 2009 May 5.

PMID:
19415305
11.

Costs associated with capecitabine or 5-fluorouracil monotherapy after surgical resection in patients with colorectal cancer.

Chu E, Shi N, Wei W, Bendell JC, Cartwright T.

Oncology. 2009;77(3-4):244-53. doi: 10.1159/000236048. Epub 2009 Sep 7.

PMID:
19738390
12.

Capecitabine (Xeloda) as monotherapy in advanced breast and colorectal cancer: effectiveness and side-effects.

Stathopoulos GP, Koutantos J, Lazaki H, Rigatos SK, Stathopoulos J, Deliconstantinos G.

Anticancer Res. 2007 May-Jun;27(3B):1653-6.

13.

[Assessment of hand-foot syndrome in cancer patients treated with capecitabine-containing chemotherapy].

Yamagiwa K, Shigematsu T, Takeda K, Shirai M, Amemori K, Sunda K, Koike C, Yamada T.

Gan To Kagaku Ryoho. 2013 Dec;40 Suppl 2:161-3. Japanese.

PMID:
24712132
14.

Significant association between hand-foot syndrome and efficacy of capecitabine in patients with metastatic breast cancer.

Azuma Y, Hata K, Sai K, Udagawa R, Hirakawa A, Tohkin M, Ryushima Y, Makino Y, Yokote N, Morikawa N, Fujiwara Y, Saito Y, Yamamoto H.

Biol Pharm Bull. 2012;35(5):717-24.

15.

Single-agent capecitabine in patients with metastatic colorectal cancer refractory to 5-fluorouracil/leucovorin chemotherapy.

Lee JJ, Kim TM, Yu SJ, Kim DW, Joh YH, Oh DY, Kwon JH, Kim TY, Heo DS, Bang YJ, Kim NK.

Jpn J Clin Oncol. 2004 Jul;34(7):400-4.

PMID:
15342667
16.
17.

Phase II study of capecitabine in patients with fluorouracil-resistant metastatic colorectal carcinoma.

Hoff PM, Pazdur R, Lassere Y, Carter S, Samid D, Polito D, Abbruzzese JL.

J Clin Oncol. 2004 Jun 1;22(11):2078-83.

PMID:
15169794
18.

Capecitabine in the management of colorectal cancer.

Maroun JA.

Expert Rev Anticancer Ther. 2001 Oct;1(3):327-33.

PMID:
12113099
19.
20.

Compliance and effective management of the hand-foot syndrome in colon cancer patients receiving capecitabine as adjuvant chemotherapy.

Son HS, Lee WY, Lee WS, Yun SH, Chun HK.

Yonsei Med J. 2009 Dec 31;50(6):796-802. doi: 10.3349/ymj.2009.50.6.796. Epub 2009 Dec 18.

Supplemental Content

Support Center